The immunotherapy nivolumab (Opdivo, Bristol Myers Squibb) after surgery increased bladder cancer patients’ chance of staying cancer-free compared with those who received placebo, according to three-year follow-up results from the phase 3 CheckMate 274 trial. Patients in the study had urothelial cancer of the bladder or upper urinary tract and had tumor features indicating a high risk for recurrence. The findings regarding nivolumab, a monoclonal antibody immune checkpoint inhibitor, were
MARCH 29, 2023